calcitonin salmon
Trade name: Calcimar
Approved
Jun 1, 1973
Calcitonin-salmon is a polypeptide hormone secreted by the parafollicular cells of the ultimobranchial gland of salmon fish. Calcitonin-salmon Nasal Spray is a polypeptide of 32 amino acids manufactured by recombinant DNA technology and is identical to calcitonin produced by salmon fish or chemical synthesis. Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts. Single injections of calcitonin cause a marked transient inhibition of the ongoing bone resorptive process. With prolonged use, there is a persistent, smaller decrease in the rate of bone resorption. Histologically, this is associated with a decreased number of osteoclasts and an apparent decrease in their resorptive activity. In vitro studies have shown that calcitonin-salmon causes inhibition of osteoclast function with loss of the ruffled osteoclast border responsible for resorption of bone. Calcitonin-salmon Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. — NCATS
Clinical trial activity
26 trials · 22 clinical orgs · 17 marketing orgs
Earliest trial started Nov 1, 1992 (NCT00004358)
Timeline
1970s
- Jun 1, 1973
Earliest FDA Approval
- Jun 1, 1975
Rhone Poulenc — First NDA Organization
- Jun 1, 1975
Rhone Poulenc — NDA Organization
- Apr 17, 1978
Sanofi-Aventis — NDA Secondary Org
1980s
- Jul 3, 1986
Mylan — NDA Secondary Org
1990s
- Jan 1, 1992
Earliest Phase 2 Sponsor(trial)
- Aug 17, 1995
PHARMOBEDIENT — Marketing Organization
2000s
- Jan 1, 2002
Earliest Phase 3 Sponsor(trial)
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
- Aug 12, 2005
Upsher-Smith Laboratories — NDA Secondary Org
- Nov 17, 2008
Apotex — Marketing Organization
- Jun 8, 2009
Par Pharmaceuticals — Marketing Organization
- Jun 8, 2009
PH HEALTH — Marketing Organization
2020s
- May 14, 2021
Custopharm Inc — Marketing Organization
- Nov 10, 2021
Bristol-Myers Squibb — Marketing Organization
- Apr 11, 2024
Dr. Reddy's Laboratories — Marketing Organization
- Sep 20, 2024
Cipla — Marketing Organization
- Dec 5, 2024
Fresenius — Marketing Organization
- Jul 9, 2025
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Sep 26, 2025
Amneal Pharmaceuticals — Marketing Organization
- Mar 4, 2026
Zydus Discovery DMCC — Marketing Organization
Indications
Studied for
Mechanism of action
- Calcitonin receptorAGONIST
CALCR agonist
Approval history
- approvedJun 1, 1973
Chemistry & pharmacology
SMILES
CNC(Cc1ccccc1)C(=O)C(C)C2CC(=O)NCCCC(CC(=C)C(Cc3c[nH]cn3)C(C)C(=O)C(Cc4ccccc4)CC(=O)C(CCCCN)C(C)C2=C)C(=O)C- Mol. weight
- 834.16 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- WikipediaCalcitonin ↗
- NCATS7SFC6U2VI5 ↗
- ChEMBLCHEMBL2107951 ↗
- ChEMBLCHEMBL3989767 ↗
- ChEMBLCHEMBL1201445 ↗
- ChEMBLCHEMBL1201661 ↗
- ChEMBLCHEMBL359713 ↗
Also known as
- calcihexal
- calcimar
- calcimar
- calcimar
- calcimar
- calcimar
- calcitare
- calcitonin
- calcitonin
- calcitonin
- calcitonin
- calcitonin salmon
- calcitonin salmon
- calcitonin salmon
- calcitonin salmon
- calcitonin salmon
- calcitonin salmon
- calcitonin (salmon)
- calcitonin (salmon)
- calcitonin (salmon)
- calcitonin (salmon)
- calcitonin (salmon)
- calcitonin-salmon
- calcitonin-salmon
- calcitonin-salmon
- calcitonin, salmon
- calcitonin, salmon
- calcitonin, salmon
- calcitonin salmon recombinant
- calcitonin salmon recombinant
- calcitonin salmon recombinant
- calcitonin salmon recombinant
- calcitonin salmon recombinant
- calcitonin (salmon synthetic)
- calcitonin (salmon synthetic)
- calcitonin (salmon synthetic)
- calcitonin (salmon synthetic)
- calcitonin (salmon synthetic)
- calsynar
- calsynar
- forcaltonin
- forcaltonin
- forcaltonin
- fortical
- fortical
- fortical
- leppin
- miacalcic
- miacalcic
- miacalcic
- miacalcin
- miacalcin
- miacalcin
- miacalcin
- polycal
- recombinant salmon calcitonin
- recombinant salmon calcitonin
- recombinant salmon calcitonin
- salcatonin
- salmon calcitonin
- salmon calcitonin
- salmon calcitonin
- salmon calcitonin
- salmon calcitonin
- salmon calcitonin
- salmon calcitonin (1-32)
- synthetic salmon calcitonin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03812991 | Phase 4 | Feb 28, 2019 | University of Missouri |
| NCT02115360 | N/A | Apr 1, 2014 | Tanta University |
| NCT01652573 | N/A | Mar 1, 2011 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Yale University |
| NCT01292187 | Phase 2 | Jan 1, 2011 | Tarsa Therapeutics, Inc. |
| NCT00959764 | Phase 3 | Jun 1, 2009 | Tarsa Therapeutics, Inc. |
| NCT00803686 | Phase 2 | Dec 1, 2008 | Bio-Kinetic Clinical Applications, Tarsa Therapeutics, Inc. |
| NCT00754884 | Phase 4 | Oct 1, 2008 | Unidad de Investigacion en Enfermedades Cronico-Degenerativas |
| NCT00704847 | Phase 3 | Jun 1, 2008 | Nordic Bioscience, Novartis |
| NCT00688077 | N/A | May 1, 2008 | Rijnstate Hospital |
| NCT00620854 | Phase 2 | Feb 1, 2008 | Bio-Kinetic Clinical Applications, Tarsa Therapeutics, Inc. |
| NCT02358304 | Phase 2 | Sep 1, 2007 | University of Tehran |
| NCT00478335 | N/A | May 1, 2007 | Aarhus University, University of Colorado, Denver |
| NCT00444808 | Phase 4 | Feb 1, 2007 | University of Montreal |
| NCT00486369 | Phase 1 | Jan 1, 2007 | Nordic Bioscience, Novartis |
| NCT00372099 | Phase 3 | Jan 1, 2007 | University of Geneva |
| NCT00414973 | Phase 3 | Dec 1, 2006 | Eli Lilly |
| NCT00395395 | Phase 1 | Oct 1, 2006 | Novartis |
| NCT00411125 | Phase 1 | Aug 1, 2006 | Novartis |
| NCT00486317 | Phase 1 | Oct 1, 2005 | Nordic Bioscience, Novartis |
| NCT00114803 | N/A | Jan 1, 2004 | Crohn's and Colitis Foundation, Harvard University, National Institutes of Health (NIH) |
Organizations
Research & Development (22)
Marketing (18)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amneal Pharmaceuticals | For profit | MKTG | Sep 26, 2025 |
| Apotex | For profit | MKTG | Nov 17, 2008 |
| Bristol-Myers Squibb | For profit | MKTG | Nov 10, 2021 |
| Cipla | For profit | MKTG | Sep 20, 2024 |
| Custopharm Inc | For profit | MKTG | May 14, 2021 |
| Dr. Reddy's Laboratories | For profit | MKTG | Apr 11, 2024 |
| Fresenius | For profit | MKTG | Dec 5, 2024 |
| Mylan | For profit | NDA2 | Jul 3, 1986 |
| PH HEALTH | For profit | MKTG | Jun 8, 2009 |
| PHARMOBEDIENT | For profit | MKTG | Aug 17, 1995 |
| Par Pharmaceuticals | For profit | MKTG | Jun 8, 2009 |
| Par Pharmaceuticals | For profit | SYN | Nov 10, 2021 |
| Rhone Poulenc | For profit | NDA | Jun 1, 1975 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Jul 9, 2025 |
| Sanofi-Aventis | For profit | NDA2 | Apr 17, 1978 |
| Teligent Pharmaceuticals | For profit | MKTG | — |
| Upsher-Smith Laboratories | For profit | NDA2 | Aug 12, 2005 |
| Zydus Discovery DMCC | For profit | MKTG | Mar 4, 2026 |